NO20004251L - Humanized anti-CEA high affinity monoclonal antibodies - Google Patents

Humanized anti-CEA high affinity monoclonal antibodies

Info

Publication number
NO20004251L
NO20004251L NO20004251A NO20004251A NO20004251L NO 20004251 L NO20004251 L NO 20004251L NO 20004251 A NO20004251 A NO 20004251A NO 20004251 A NO20004251 A NO 20004251A NO 20004251 L NO20004251 L NO 20004251L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
high affinity
humanized anti
affinity monoclonal
tag
Prior art date
Application number
NO20004251A
Other languages
Norwegian (no)
Other versions
NO20004251D0 (en
Inventor
William Henry Kerr Anderson
Philip R Tempest
Frank J Carr
William J Harris
Kathryn Armour
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of NO20004251D0 publication Critical patent/NO20004251D0/en
Publication of NO20004251L publication Critical patent/NO20004251L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Nye humaniserte monoklonale antistoffer, humaniserte antistoff-fragmenter og derivater derav som spesifikt binder TAG-72 er beskrevet, samt fremgangsmåter for fremstilling derav. Disse humaniserte antistoffene er nyttige for behandling av cancer som uttrykker TAG-72 samt for diagnostiske formål, f.eks iv vivo billed-dannelse av tumorer eller cancerceller som uttrykker TAG-72.New humanized monoclonal antibodies, humanized antibody fragments and derivatives thereof that specifically bind TAG-72 are described, as well as methods for their production. These humanized antibodies are useful for the treatment of cancers that express TAG-72 as well as for diagnostic purposes, eg iv vivo imaging of tumors or cancer cells that express TAG-72.

NO20004251A 1998-02-25 2000-08-24 Humanized anti-CEA high affinity monoclonal antibodies NO20004251L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003680 WO1999043817A1 (en) 1998-02-25 1998-02-25 High affinity humanized anti-cea monoclonal antibodies

Publications (2)

Publication Number Publication Date
NO20004251D0 NO20004251D0 (en) 2000-08-24
NO20004251L true NO20004251L (en) 2000-10-24

Family

ID=22266464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004251A NO20004251L (en) 1998-02-25 2000-08-24 Humanized anti-CEA high affinity monoclonal antibodies

Country Status (7)

Country Link
EP (1) EP1056859A1 (en)
JP (1) JP2002504372A (en)
AU (1) AU752494B2 (en)
CA (1) CA2321947A1 (en)
IL (1) IL138022A0 (en)
NO (1) NO20004251L (en)
WO (1) WO1999043817A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025565A2 (en) * 2001-09-21 2003-03-27 Caprion Pharmaceuticals Inc. Preparation of highly-purified plasma membranes
CA2609142C (en) * 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
PL2681244T3 (en) * 2011-03-02 2018-04-30 Roche Glycart Ag Cea antibodies
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
CN111499750B (en) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 High-neutralization-activity nano antibody for resisting carcinoembryonic antigen and application thereof
TW202115125A (en) 2019-06-26 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 Anti-cea antibody and the use thereof
IL300497A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Compositions and methods for treating ceacam positive cancers
MX2023002041A (en) 2020-08-20 2023-04-27 A2 Biotherapeutics Inc Compositions and methods for treating mesothelin positive cancers.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
HUP9901562A3 (en) * 1996-05-04 2000-06-28 Astrazeneca Ab Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Also Published As

Publication number Publication date
EP1056859A1 (en) 2000-12-06
WO1999043817A1 (en) 1999-09-02
IL138022A0 (en) 2001-10-31
AU752494B2 (en) 2002-09-19
JP2002504372A (en) 2002-02-12
AU6338898A (en) 1999-09-15
CA2321947A1 (en) 1999-09-02
NO20004251D0 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
WO1999004265A8 (en) Cancer associated nucleic acids and polypeptides
NO175944C (en) Monoclonal antibodies for use in in vitro detection of tumor-associated mucin antigen, and hybridoma cell lines producing these
DE69734109D1 (en) Humanization of anti-carcinoembryonic antigen anti-idiotypic antibodies and their use as a tumor vaccine and for labeling
CY1113326T1 (en) HUMAN ANTIBODIES THAT CONNECT HUMAN IL-12 AND ITS PRODUCTION METHODS
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
TR200200937T2 (en) Compositions for the treatment of ovarian cancer.
HK1074634A1 (en) Internalizing antibodies specific for the raag10 cell surface target
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
MX9701859A (en) Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor.
HK1064621A1 (en) Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
MX9504802A (en) Anti-egfr single-chain fvs and anti-egfr antibodies.
HUP9901562A2 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
MXPA03000527A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer.
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
AU2829889A (en) Sf-25 colon adenocarcinoma antigen, and antibodies which recognize this antigen
EA200601405A1 (en) HUMANIZED ANTIBODY
WO2003064593A3 (en) Antigen panels and methods of using the same
NO20004251L (en) Humanized anti-CEA high affinity monoclonal antibodies
NO20004250D0 (en) Humanized anti-TAG-72 high affinity monoclonal antibodies
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
NO20063155L (en) Anti-IGF-I receptor antibody
WO2003024302A3 (en) Detection and treatment of cancers of breast
BR9815775A (en) High affinity humanized carcinoembryonic (CEA) monoclonal antibodies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application